{"id":"cotrimoxazole-dispersible-tablet","safety":{"commonSideEffects":[{"rate":"3-6","effect":"Rash"},{"rate":"2-4","effect":"Nausea"},{"rate":"1-3","effect":"Vomiting"},{"rate":"2-4","effect":"Diarrhea"},{"rate":"1-2","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Stevens-Johnson syndrome"}]},"_chembl":{"chemblId":"CHEMBL58061","moleculeType":"Small molecule","molecularWeight":"543.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. Together, they block the bacterial synthesis of dihydrofolate and tetrahydrofolate, essential cofactors for nucleotide synthesis. This synergistic dual inhibition is bactericidal and provides broad-spectrum coverage against many gram-positive and gram-negative organisms.","oneSentence":"Cotrimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:42.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (urinary tract infections, respiratory tract infections, otitis media)"},{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"},{"name":"Toxoplasmosis"}]},"trialDetails":[{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT05843968","phase":"PHASE2","title":"Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome","status":"RECRUITING","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2023-01-29","conditions":"Nephrotic Syndrome in Children","enrollment":46},{"nctId":"NCT04395365","phase":"PHASE3","title":"Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis","status":"UNKNOWN","sponsor":"University College, London","startDate":"2019-06-30","conditions":"Spontaneous Bacterial Peritonitis","enrollment":442},{"nctId":"NCT00934492","phase":"PHASE3","title":"Cotrimoxazole Prophylaxis in Severely Malnourished Children","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-11","conditions":"Nutrition Disorders, Life-threatening Infection","enrollment":1781}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cosatrim","Septrin","Bactrim"],"phase":"phase_3","status":"active","brandName":"Cotrimoxazole dispersible tablet","genericName":"Cotrimoxazole dispersible tablet","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cotrimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication. Used for Bacterial infections (urinary tract infections, respiratory tract infections, otitis media), Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}